Korro Bio (KRRO)
Develops RNA-editing therapeutics around OPERA and GalNAc-delivered liver programs.
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 98.13% | 14.45M shares | |
|---|---|---|---|
| 112 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 16.35% | 2.41M shares | |
| 7 holders · as of Sep 15, 2026 | |||
| Adds to | 114.48% | ||
14.73M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (14.73M in the company's Sep 23, 2026 report, 9.95M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 114.48%; nothing is left for Other.
13F, as of Jun 30, 2026
112 holders · 14.45M shares · 22 new positions · 68 increased · 21 reduced · 13 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| LYNX1 Capital Management LP | 1.54M | 10.45% | 0 | Aug 13, 2026 |
| Nea Management Company, LLC | 1.30M | 8.81% | 0 | Aug 14, 2026 |
| VR Adviser, LLC | 1.01M | 6.86% | 0 | Aug 14, 2026 |
| Atlas Venture Life Science Advisors, LLC | 962.9K | 6.54% | −174.3K | Aug 13, 2026 |
| Balyasny Asset Management L.P. | 951.8K | 6.46% | −88.3K | Aug 14, 2026 |
| BlackRock, Inc. | 817.6K | 5.55% | +357.6K | Aug 7, 2026 |
| Affinity Asset Advisors, LLC | 706.9K | 4.80% | 0 | Aug 13, 2026 |
| Nantahala Capital Management, LLC | 660.0K | 4.48% | 0 | Aug 19, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Lynx1 Capital Management LP | 10.70% | 1.54M | 13G | Apr 2, 2026 |
| Venrock Healthcare Capital Partners III, L.P. | 9.90% | 1.49M | 13G | Mar 17, 2026 |
| Ali Behbahaniincl. Nea 17 GP, LLC, New Enterprise Associates 17, L.P. +9 more | 9.90% | 1.46M | 13D | Mar 12, 2026 |
| Nantahala Capital Management, LLC | 6.37% | 600.0K | 13G | Feb 13, 2026 |
| BlackRock, Inc. | 5.20% | 747.5K | 13G | Jul 29, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 14, 2026 | Jean Francois Formeladirector | Sale · 2 lots | 38,490 | $14.12 | 132,650 |
| Sep 11, 2026 | Jean Francois Formeladirector | Sale · 2 lots | 10,200 | $13.99 | 139,252 |
| Sep 11, 2026 | Oliver Dolanofficer: Senior Vice President, Finance | Sale | 5 | $13.72 | 16,241 |
| Sep 9, 2026 | Oliver Dolanofficer: Senior Vice President, Finance | Sale | 6 | $13.60 | 16,246 |
| Sep 8, 2026 | Oliver Dolanofficer: Senior Vice President, Finance | Sale | 7,347 | $13.51 | 16,252 |
| Aug 26, 2026 | Jean Francois Formeladirector | Sale · 2 lots | 300 | $13.96 | 141,002 |
| Aug 19, 2026 | Jean Francois Formeladirector | Sale · 2 lots | 28,468 | $14.00 | 141,053 |
| Aug 11, 2026 | Jean Francois Formeladirector | Sale · 2 lots | 2,143 | $13.96 | 145,937 |
| Aug 10, 2026 | Lynx1 Capital Management LP10 percent owner | Purchase | 1,462 | $13.19 | 1,544,980 |
| Aug 6, 2026 | Lynx1 Capital Management LP10 percent owner | Purchase | 5,222 | $11.40 | 1,543,518 |
House and Senate disclosures
Not reported.